BG
OLMA icon

Bellevue Group’s Olema Pharmaceuticals OLMA Stock Holding History

Bellevue Group’s Portfolio OLMA Stock Details OLMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$245K Buy
16,443
+12,541
+321% +$279K 0.01% 130
2025
Q4 		$97.5K Buy
+3,902
New +$69.4K ﹤0.01% 164

Other funds holding OLMA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Bellevue Group's OLMA Position: Q1 2026 in Review

Bellevue Group increased its Olema Pharmaceuticals (OLMA) stake by 321% in Q1 2026, buying an estimated $279K and bringing the position to 16,443 shares worth $245K. The position accounts for 0.01% of the portfolio, ranked #130.

Bellevue Group first reported a position in OLMA in Q4 2025 and has held it in 2 quarters since. 195 funds tracked by Wall St. Rank hold OLMA as of Q1 2026.

  • Bellevue Group held 16,443 shares of Olema Pharmaceuticals worth $245K as of Q1 2026.
  • Bellevue Group bought 12,541 Olema Pharmaceuticals shares in Q1 2026, an estimated $279K.
  • Olema Pharmaceuticals made up 0.01% of Bellevue Group's portfolio in Q1 2026, its #130 holding.
  • Bellevue Group first reported a position in Olema Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • 195 funds tracked by Wall St. Rank held Olema Pharmaceuticals as of Q1 2026.

Based on Bellevue Group's 13F filing for Q1 2026, filed 15 May 2026.